Fig. 3.

Myelin uptake increases CD36 expression in an NRF2-dependent manner. a, b mRNA expression (n = 9 wells) and surface protein level (n = 4 wells) of CD36 in bone marrow-derived macrophages (BMDMs) treated with vehicle, myelin, and a PPARγ antagonist (GW9662, 10 μM) for 24 h (n = 9 wells). c, d mRNA expression (n = 6 wells) and relative surface protein level (n = 4 wells) of CD36 in wild-type (wt) and Nrf2-deficient (Nrf2^−/−) BMDMs treated with myelin or left untreated for 24 h. e–g mRNA expression (n = 6 wells) of Ho1, Nqo1, and Nrf2 in wt and Nrf2^−/− BMDMs treated with myelin or left untreated for 24 h. MFI, mean fluorescence intensity. Data are represented as mean ± s.e.m. *p < 0.05, **p < 0.01, and ***p < 0.001